Top Tweets for #datodxD
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: Ana Garrido-Castro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
#datoDXd FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy
Not 1️⃣, not 2️⃣, but now 3️⃣ approvals in #bcsm this month!
#vepdegestrant
#TDxd neoadj/adj
#datodxD 1st L
https://t.co/FXeEAWVkqE
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the #TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
Osimertinib plus Dato-DXd (4 or 6 mg/kg) was investigated in EGFR-mutated advanced NSCLC post-PD on first-line osimertinib. For osimertinib plus Dato-DXd 6 mg/kg, median PFS was 11.7 months; DoR and OS were encouraging. ORCHARD
#osimertinib #datodxd
https://t.co/odZaFyiNM0
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
PI: Ana Garrido-Castro #ADCs
First-line metastatic TNBC has officially changed!
The key question is no longer “chemo or not?”
It’s which ADC, for which patient, with which toxicity trade-off.
Welcome to the ADC-first era in metastatic TNBC.
#ASCO #ESMO #TNBC #BreastCancer #ADC #Sacituzumab #DatoDXd #Oncology
2025 approvals: Summary of 5 new drugs/indications in #BreastCancer & #GynOnc by Santa aka @US_FDA
1. #DatoDXd
2. #TDXd x2
3. #Imlunestrant
4. #Avutometinib/#Defactinib: Ovarian Ca
#bcsm #OncTwitter #MedTwitter #HappyHolidays #MerryChristmas
2024 approvals: Summary of 8 new drugs/indications in #BreastCancer & #GynOnc by @US_FDA
1. #Ribociclib
2. #Inavolisib
3. #Pembrolizumab x2
4. #Mirvetuximab
5. #Tisotumab
6. #Dostarlimab
7. #Durvalumab
#bcsm #gyncsm #OncTwitter #MedTwitter #HappyHolidays
2025 approvals: Summary of 9 new drugs/indications in #LungCancer by @US_FDA
1. #TelisoV
2. #Taletrectinib
3. #DatoDXd
4. #Sunvozertinib
5. #Zongertinib
6. #Lurbinectedin (w/Atezo)
7. #Sevabertinib
8. #Tarlatamab
9. SubQ #Amivantamab
#lcsm #OncTwitter #MedTwitter
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by @US_FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab
9. #Ensartinib
#lcsm #OncTwitter #MedTwitter
More data to change first-line therapy in patients with advanced triple-negative #PDL1- (or IO ineligible) #BreastCancer after #ESMO25: another great presentation by superstar @RebeccaDSing of the #TropionBreast02 trial (NO crossover allowed)
@myESMO @OncoAlert #datoDXd #bcsm
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: #AnaGarridoCastro #ADCs
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAMo8
PI: Ana Garrido-Castro #ADCs
🫁 Pooled analysis from TROPION-Lung05 & Lung01.
Datopotamab deruxtecan showed ORR 43%, DoR 7 mo, PFS 5.8 mo, OS 15.6 mo in heavily pretreated EGFR-mut NSCLC. Acceptable safety, no new signals.
📖 @JTOonline
DOI 👉🏻 https://t.co/n6CmfOGZVw
#CánCare #NSCLC #EGFR #DatoDXd #lungcancer
VJ Oncology - Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases
@VJOncology @PTarantinoMD @DanaFarber
https://t.co/XsB13iWbNw
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #DatoDXd #BreastCancer #mBC #DATOBase @CancerWorldmag
🚨 New! US expert Delphi consensus on the prevention and management of #stomatitis in patients treated with #DatopotamabDeruxtecan
🔓https://t.co/rG6o7vByPS
@hoperugo @dradityabardia @ErikaHamilton9 @jhaveri_komal @BCJoyceO @sands_jacob @stolaney1 #OralMucositis #DatoDXd
@DFCI_BreastOnc & @TheTBCRC are leading the TRADE-DXd trial, a phase 2 trial evaluating the efficacy of sequential #AntibodyDrugConjugates (trastuzumab deruxtecan (#TDXd) followed by datopotamab deruxtecan (#DatoDXd), or vice versa, for patients with advanced HER2 negative #BreastCancer.
For more information call 877-338-7425 or visit: https://t.co/7A4GxwAeyA
TROPION-PanTumor01 trial for advanced #BladderCancer. @UroDocAsh interviews Dr. Funda Meric-Bernstam @MDAndersonNews on the #TROPIONPanTumor01 trial results in #urothelialcancer. #DatoDXd shows a 25% ORR in heavily pretreated patients, with 76% maintaining disease control at 6 months! Promising durability & manageable safety. 🔬💊 Watch now > https://t.co/KgvFco8meW
#HawaiiLung25 @JSabari @nyulangone discusses #DatoDxd (Trop2 ADC) latest approval for EGFR+ NSCLC post osi progression ➡️based on Ph2 TropionLung 01,05 trials w ORR 45%
➡️ He asks the experts is Dato-Dxd a 2nd line option?
@DAVAOnc @EGFRResisters
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
119.2M followers
Cristiano Ronaldo
@cristiano
111.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.2M followers
KATY PERRY
@katyperry
88.3M followers
Taylor Swift
@taylorswift13
82.2M followers
Lady Gaga
@ladygaga
73.7M followers
Virat Kohli
@imvkohli
70.9M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.3M followers
Neymar Jr
@neymarjr
63.8M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.4M followers
X
@x
60.8M followers